Managing Your Symptoms: Medication Options
At a Glance
Medications can reduce muscle stiffness in myotonia congenita, with mexiletine usually the best-studied option and lamotrigine a supported alternative. Treatment must be individualized because heart risks, side effects, slow dose increases, and drug interactions require medical supervision.
Treatment for myotonia congenita is focused entirely on managing symptoms and improving your quality of life. Because this condition is not a progressive muscular dystrophy, there is no “cure” that changes your genes, but there are effective ways to reduce the muscle stiffness that can interfere with your daily activities [1][2].
Whether or not to start medication is a personal decision to discuss with your doctor. Many people find that their symptoms are mild enough to manage with the “warm-up” phenomenon (moving until the stiffness fades), while others find that the stiffness is frequent or severe enough to require daily treatment [1][3]. Medications should only be started, adjusted, or stopped under the strict supervision of your prescriber.
First-Line Treatment: Mexiletine
Mexiletine is currently the best-studied medication for reducing muscle stiffness in nondystrophic myotonia [4][5]. It works by stabilizing the electrical signals in your muscle cells, making them less likely to “fire” excessively [5]. (Note: Mexiletine is used “off-label” for myotonia in many jurisdictions).
- Dosing: In adults, treatment often begins at a low dose (around 200 mg per day) and is gradually increased by your doctor up to 600 mg per day, depending on how you respond [5][6].
- Effectiveness: Large studies have shown that many patients experience a significant reduction in reported stiffness and an improvement in overall quality of life when taking this medication [4][5].
- Cardiac Safety: Because mexiletine is also a heart rhythm medication (a class Ib antiarrhythmic), your doctor must ensure your heart is healthy before you start. This typically involves a review of your cardiac history and an Electrocardiogram (ECG) to check your heart’s electrical patterns [1][7]. However, an ECG alone is not a guarantee of safety; seek urgent care if you experience fainting, severe dizziness, or new palpitations.
Managing Side Effects of Mexiletine
The most common reason people stop taking mexiletine is gastrointestinal (GI) upset. Up to 70% of people in some studies reported some level of stomach discomfort [8].
- Common Issues: Indigestion (dyspepsia), nausea, and heartburn are the most frequent complaints [6][4].
- Management: Taking the medication with food or using acid-reducing treatments can sometimes help, but if the pain is severe, your doctor may suggest an alternative medication [6].
Alternative Medications
If mexiletine is not effective, causes too many side effects, or is unsafe due to heart concerns, other options are available.
Lamotrigine
Lamotrigine is a well-supported alternative that has shown significant benefits in reducing muscle stiffness in clinical trials [9][4].
- Pros: It is often better tolerated by the stomach than mexiletine [10].
- Precautions: It must be started at a very low dose and increased very slowly over several weeks. This is to minimize the risk of a serious skin rash [9][11]. Seek urgent medical advice immediately if you develop a new rash, blistering or peeling skin, mouth or eye sores, fever, or facial swelling.
Ranolazine
Ranolazine is a newer off-label option that is sometimes considered if other treatments fail. While preliminary studies (including a small 13-person pilot) showed it could reduce stiffness and weakness, the evidence is not yet as strong as it is for mexiletine or lamotrigine [12][13]. It requires careful cardiac monitoring due to QT prolongation concerns and drug interactions.
Older Options
In some cases, doctors may still use older anti-seizure medications like carbamazepine or phenytoin [14]. While these can be effective for some, they generally have less modern research supporting their use for myotonia compared to the newer options [4].
Making a Treatment Plan
Your treatment should be highly individualized. Some patients, under a prescriber’s plan, may only take medication during the winter when cold weather makes their stiffness worse, while others take it year-round [3].
Before starting any treatment, ensure your doctor has a complete list of all your other medications, as drugs like certain antifungals or macrolide antibiotics can interact dangerously with these muscle-stiffness treatments [15]. Regular follow-ups with a neurologist who specializes in neuromuscular diseases can help you find the right balance between symptom relief and side-effect management.
Common questions in this guide
What medicine is usually used first for myotonia congenita?
Do I need heart tests before taking mexiletine?
What can I do if mexiletine upsets my stomach?
Can lamotrigine be used if mexiletine is not suitable?
What other medicines can treat myotonia congenita?
Can I take myotonia medication only when my stiffness is worse?
Can my other medicines interact with treatments for myotonia congenita?
Get notified when new evidence is published on Thomsen and Becker disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (15)
- 1
Recommendations of an expert group for the cardiac assessment of non-dystrophic myotonia adult patients treated with mexiletine.
Vicart S, Wahbi K, Duchateau J, et al.
Neuromuscular disorders : NMD 2024; (44()):104464 doi:10.1016/j.nmd.2024.104464.
PMID: 39368428 - 2
Defective Gating and Proteostasis of Human ClC-1 Chloride Channel: Molecular Pathophysiology of Myotonia Congenita.
Jeng CJ, Fu SJ, You CY, et al.
Frontiers in neurology 2020; (11()):76 doi:10.3389/fneur.2020.00076.
PMID: 32117034 - 3
Expert Insights from a Delphi-driven Neurologists' Panel: Real-world Mexiletine use in Patients with Myotonic Disorders in Italy.
Lidonnici D, Brambilla P, Ravasio R, et al.
Journal of neuromuscular diseases 2024; (11(2)):411-423 doi:10.3233/JND-230115.
PMID: 38306059 - 4
Drug treatment for myotonia.
Spillane J, Trip J, Drost G, et al.
The Cochrane database of systematic reviews 2025; (4()):CD004762 doi:10.1002/14651858.CD004762.pub3.
PMID: 40197813 - 5
Efficacy and safety of mexiletine in non-dystrophic myotonias: A randomised, double-blind, placebo-controlled, cross-over study.
Vicart S, Franques J, Bouhour F, et al.
Neuromuscular disorders : NMD 2021; (31(11)):1124-1135 doi:10.1016/j.nmd.2021.06.010.
PMID: 34702654 - 6
Long-Term Safety and Usefulness of Mexiletine in a Large Cohort of Patients Affected by Non-dystrophic Myotonias.
Modoni A, D'Amico A, Primiano G, et al.
Frontiers in neurology 2020; (11()):300 doi:10.3389/fneur.2020.00300.
PMID: 32655465 - 7
Effectiveness and safety of mexiletine versus placebo in patients with myotonia: a systematic review and meta-analysis.
Elettreby AM, Elnaga AAA, Alsaied MA, et al.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2024; (45(8)):3989-4001 doi:10.1007/s10072-024-07412-z.
PMID: 38403671 - 8
Effect of Mexiletine on Muscle Stiffness in Patients With Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials.
Stunnenberg BC, Raaphorst J, Groenewoud HM, et al.
JAMA 2018; (320(22)):2344-2353 doi:10.1001/jama.2018.18020.
PMID: 30535218 - 9
The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study.
Andersen G, Hedermann G, Witting N, et al.
Brain : a journal of neurology 2017; (140(9)):2295-2305 doi:10.1093/brain/awx192.
PMID: 29050397 - 10
Mexiletine versus lamotrigine in non-dystrophic myotonias: a randomised, double-blind, head-to-head, crossover, non-inferiority, phase 3 trial.
Vivekanandam V, Skorupinska I, Jayaseelan DL, et al.
The Lancet. Neurology 2024; (23(10)):1004-1012 doi:10.1016/S1474-4422(24)00320-X.
PMID: 39304240 - 11
Lamotrigine Therapy: Relation Between Treatment of Bipolar Affective Disorder and Incidence of Stevens-Johnson Syndrome-A Narrative Review of the Existing Literature.
Żełabowski K, Wojtysiak K, Ratka Z, et al.
Journal of clinical medicine 2025; (14(12)) doi:10.3390/jcm14124103.
PMID: 40565849 - 12
Open-label trial of ranolazine for the treatment of myotonia congenita.
Arnold WD, Kline D, Sanderson A, et al.
Neurology 2017; (89(7)):710-713 doi:10.1212/WNL.0000000000004229.
PMID: 28710329 - 13
Treatment Updates for Neuromuscular Channelopathies.
Jitpimolmard N, Matthews E, Fialho D
Current treatment options in neurology 2020; (22(10)):34 doi:10.1007/s11940-020-00644-2.
PMID: 32848354 - 14
Non-dystrophic myotonia Chilean cohort with predominance of the SCN4A Gly1306Glu variant.
Avila-Smirnow D, Vargas Leal CP, Beytía Reyes MLA, et al.
Neuromuscular disorders : NMD 2020; (30(7)):554-561 doi:10.1016/j.nmd.2020.04.006.
PMID: 32593548 - 15
Persistence of a Posaconazole-Mediated Drug-Drug Interaction With Ranolazine After Cessation of Posaconazole Administration: Impact of Obesity and Implications for Patient Safety.
Chow CR, Harmatz JS, Ryan MJ, Greenblatt DJ
Journal of clinical pharmacology 2018; (58(11)):1436-1442 doi:10.1002/jcph.1257.
PMID: 29749631
This page is for informational purposes only and does not constitute medical advice about myotonia congenita medications. Your neurologist or prescriber should guide medication choice, dose changes, heart monitoring, and management of side effects.